Related Experiment Video
Updated: Jun 18, 2026
16:56
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
The future of sublingual immunotherapy.
1Institute of Pediatrics, Department of Medical and Surgical specialty and Public Health, Ospedale Santa Maria della Misericordia, Perugia, Italy. marcucci@unipg.it
International Journal of Immunopathology and Pharmacology
|December 1, 2009
Summary
Sublingual immunotherapy (SLIT) shows promise for treating allergies, with future developments including improved delivery methods and new applications like food allergies. Research is exploring tablets, adjuvants, and recombinant allergens to enhance efficacy and patient convenience.
Area of Science:
- Allergy and Immunology
- Immunotherapy Research
- Clinical Trials
Background:
- Sublingual immunotherapy (SLIT) is a widely used allergen immunotherapy in Europe.
- International consensus supports SLIT, with growing acceptance in the USA.
- Current SLIT methods can be enhanced for improved efficacy and patient experience.
Purpose of the Study:
- To explore potential improvements and future directions for SLIT.
- To investigate novel materials, adjuvants, and recombinant allergens for SLIT.
- To assess the applicability of SLIT in new areas, such as food allergies.
Main Methods:
- Review of existing literature and consensus publications on SLIT.
- Analysis of emerging technologies like SLIT tablets and adjuvant therapies (CpG, VitD3-Dex, Lactobacillus plantarum).
- Examination of component-resolved diagnosis using recombinant allergens and SLIT for food allergies.
Main Results:
- SLIT tablets offer potential for increased patient convenience with no-updosing schedules.
- Adjuvants like CpG, VitD3-Dex, and Lactobacillus plantarum show promise for enhancing SLIT.
- Component-resolved diagnosis may enable tailored immunotherapy, though SLIT studies are pending.
- SLIT demonstrated increased tolerance in a hazelnut allergy study, suggesting potential for other food allergies.
Conclusions:
- SLIT is a valuable treatment with significant potential for future advancements.
- Novel materials, adjuvants, and recombinant allergens are key areas for SLIT development.
- SLIT shows promise for treating food allergies, warranting further clinical trials.
